Rezolute to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company focused on developing transformative therapies for rare diseases, has announced its participation in two upcoming investor conferences. The company will attend Guggenheim's Inaugural Healthcare Innovation Conference from November 11-13, 2024, and the Jefferies London Healthcare Conference from November 19-21, 2024.
Management will be available for one-on-one meetings with investors during both conferences. Interested investors can schedule meetings through their Guggenheim and Jefferies representatives.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the following investor conferences:
Event: Guggenheim’s Innaugural Healthcare Innovation Conference
Date: November 11-13, 2024
Event: Jefferies London Healthcare Conference
Date: November 19-21, 2024
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Contact:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
